Better days for people with Parkinson’s disease.
Adamant Health’s unique technology to analyse Parkinson’s disease symptoms is based on over 15 years of academic research at the University of Eastern Finland. With the technology, clinicians have several days detailed visibility to the patient’s symptoms and is able to optimise the treatment accordingly. Pharma companies benefit from the objective and long-term RW data in their clinical and post market studies and can utilise it as complementary diagnostics tool for personalised medication.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 13, 2022 | Seed | €2.20M | 1 | — | — | Detail |
Dec 15, 2020 | Pre-seed | — | 1 | — | — | Detail |